858353-45-4

Usage

Uses

Used in Organic Chemistry:
(9H-fluoren-9-yl)methyl 1,2-dimethylhydrazine-1-carboxylate is used as a synthetic intermediate for the creation of various organic compounds. Its unique structure allows it to serve as a building block in the synthesis of complex molecules, contributing to the development of new materials and chemical products.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, (9H-fluoren-9-yl)methyl 1,2-dimethylhydrazine-1-carboxylate may be utilized as a precursor in the development of new drugs. Its structural properties could be harnessed to design molecules with specific therapeutic effects, potentially leading to advancements in medicinal chemistry.
Used in Material Science:
(9H-fluoren-9-yl)methyl 1,2-dimethylhydrazine-1-carboxylate may also find applications in material science, where it could be employed in the synthesis of novel materials with unique properties. These materials could have applications in various fields, such as electronics, optics, or even in the development of new types of polymers.

Upstream product

• 1301147-43-2 C₁₇H₁₆N₂O₂ 
• 540-73-8 1,2-Dimethylhydrazine 
• 28920-43-6 (fluorenylmethoxy)carbonyl chloride 
• 250280-32-1 (9H-fluoren-9-yl)methyl1-methylhydrazinecarboxylate 
• 73664-86-5 1,2-dimethylhydrazine hydrochloride 
• 306-37-6 N,N'-Dimethylhydrazine dihydrochloride 

Relevant academic research and scientific papers

ANTI-CD22 ANTIBODY-MAYTANSINE CONJUGATES, COMBINATIONS, AND METHODS OF USE THEREOF

The present disclosure provides methods for treating a cancer or resistant cancer with a combination of an anti-CD22 antibody-maytansine conjugate and one or more anti-cancer agents. The disclosure also encompasses methods for sensitizing a cancer with such combinations. Also provided are pharmaceutical compositions including such combinations.

Two-fold Bioorthogonal Derivatization by Different Formylglycine-Generating Enzymes

Formylglycine-generating enzymes are of increasing interest in the field of bioconjugation chemistry. They catalyze the site-specific oxidation of a cysteine residue to the aldehyde-containing amino acid Cα-formylglycine (FGly). This non-canonical residue can be generated within any desired target protein and can subsequently be used for bioorthogonal conjugation reactions. The prototypic formylglycine-generating enzyme (FGE) and the iron-sulfur protein AtsB display slight variations in their recognition sequences. We designed specific tags in peptides and proteins that were selectively converted by the different enzymes. Combination of the different tag motifs within a single peptide or recombinant protein enabled the independent and consecutive introduction of two formylglycine residues and the generation of heterobifunctionalized protein conjugates.

ANTI-CD22 ANTIBODY-MAYTANSINE CONJUGATES AND METHODS OF USE THEREOF

The present disclosure provides anti-CD22 antibody-maytansine conjugate structures. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.

ANTI-HER2 ANTIBODY-MAYTANSINE CONJUGATES AND METHODS OF USE THEREOF

The present disclosure provides anti-HER2 antibody-maytansine conjugate structures. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.

Exploring the effects of linker composition on site-specifically modified antibody-drug conjugates

In the context of antibody-drug conjugates (ADCs), noncleavable linkers provide a means to deliver cytotoxic small molecules to cell targets while reducing systemic toxicity caused by nontargeted release of the free drug. Additionally, noncleavable linker

Nβ-Fmoc- Nβ-Methyl-aza-β3- amino acids

The potential of peptides as drug candidates is limited by their poor pharmacokinetic properties. Many peptides have a short half-life, in vivo half-life, and insufficient oral availability. Inspired by the N-methylation of peptides as a promising way to